New cancer drug shows promise in mesothelioma trial

A breakthrough cancer drug has demonstrated encouraging results in clinical trials for mesothelioma, a rare and aggressive malignancy caused by asbestos exposure. Mesothelioma develops when inhaled asbestos fibers lodge in the lungs, triggering chronic inflammation that can lead to tumor formation decades after initial exposure. With approximately 30,000 new diagnoses worldwide annually, this therapeutic advancement offers hope for patients with this historically difficult-to-treat disease. The drug's promising trial results represent a significant step forward in improving treatment options and outcomes for mesothelioma patients.